Navigation Links
Common Anaesthetic Drug Can Kill Brain Cells

The commonly used anaesthetic isoflurane could kill brain cells and raise the risk of Alzheimer's, suggests a new study questioning the safety of the drug.

Isoflurane is an anaesthetic, which is inhaled and used when general anaesthesia is required. //

Many people, especially the elderly, suffer from postoperative cognitive dysfunction after anaesthesia as well as scrambling and delirium that can last six hours or two weeks or months, reported the health portal HealthCentral.

'To me, a big dose of isoflurane mimics a stroke or a bang to the head, and you don't want that as a risk factor for Alzheimer's disease at any age,' said Rudolph Tanzi of the Massachusetts General Institute for Neurodegenerative Disease who led the study.

Tanzi's team exposed cells that had an amyloid-beta protein, a protein that restores brain function, to isoflurane for six hours.

The researchers found that isoflurane caused these cells to die. 'It also caused the cell to overproduce the toxic molecule responsible for the pathology of Alzheimer's disease, particularly amyloid-beta,' Tanzi said.

This is a warning, he said. 'Isoflurane may be one reason why the elderly are more prone to cognitive dysfunction following anaesthesia.'

The researcher believes that isoflurane should be avoided when possible. 'We don't have enough data yet to ban isoflurane... But I'm convinced enough that I won't let my mother have it. I would advise any family or friends to stay away from isoflurane.'

Source-IANS
'"/>




Page: 1

Related medicine news :

1. Common contraception
2. Common Cold Remedy May Treat SARS
3. Common Plant Triggers Asthma
4. Pain Common in People with MS
5. Common Cold Found to Fight Cancer
6. Bullying – a Common Problem Among Childre
7. Common Medication Errors in Children
8. A Common Cause Of Allergy That Goes Unnoticed
9. Genetic Breakthrough in Common Eye Problem
10. Common Cold Found to Fight Cancer Cells
11. Side Effects Of Some Common Drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/23/2017)... ... June 23, 2017 , ... Radabaugh & Associates, a ... and business owners in North Central West Virginia, is embarking on a cooperative ... abled residents in the region. , The Stepping Stones organization offers a series ...
(Date:6/22/2017)... California (PRWEB) , ... June 22, 2017 , ... Groove ... spread the word about their high performance silicon wedding bands and all-purpose rings. Whether ... are the active, silicone rings designed just for you. , From the rock face ...
(Date:6/22/2017)... ... June 22, 2017 , ... A June 12 article in ... about an apparent lack of oral hygiene by an aged parent who had recently ... matters, suggests a number of steps, including scheduling a dentist visit. Northridge Dental Works, ...
(Date:6/20/2017)... York City (PRWEB) , ... June 20, 2017 , ... After months of negotiations, FaceCradle ... QVC Network on Wednesday, June 21. , “Introducing our product on QVC is ... for us to promote our travel pillow to more than 90 million homes in the ...
(Date:6/20/2017)... ... June 20, 2017 , ... ... the introduction of school choice can promote economic development in economically distressed urban ... has, according to the report, contributed to the economic development of the city ...
Breaking Medicine News(10 mins):
(Date:5/22/2017)... , May 22, 2017  As the ... a whole continue to make the revolutionary shift ... increasingly important for ensuring positive patient outcomes and ... stakeholders are shifting focus away from clinical trials ... effects of long-term specialty drug therapy utilization in ...
(Date:5/18/2017)... WHIPPANY, N.J. , May 17, 2017  Bayer ... growing oncology portfolio will be presented at the 53 ... Clinical Oncology (ASCO), taking place June 2-6 in ... being presented at ASCO span prostate, colorectal, liver and ... subgroup analysis from the Phase II CHRONOS-1 trial of ...
(Date:5/15/2017)... , May 15, 2017 Enterin Inc., a ... and developing novel compounds to treat Parkinson,s disease (PD), ... study is a Phase 1/2a randomized, controlled, multicenter study involving ... It will enroll 50 patients over a 9-to-12-month period. The ... in 10 patients with PD. Participating sites include ...
Breaking Medicine Technology: